Drug-coated balloons used in peripheral artery disease: experience from a single center
Jinbo Liu1, Tianrun Li2, Wei Huang1
1Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, P. R. of China.
Insights
Drug-coated balloons (DCBs) offer a safe and effective treatment for peripheral arterial disease, improving ankle-brachial index and reducing symptoms like claudication. This therapy shows promising outcomes in real-world patient populations.
Area of Science:
- Vascular Medicine
- Interventional Cardiology
- Medical Devices
Background:
- Peripheral arterial disease (PAD) is a significant cause of morbidity and mortality.
- Current treatments for PAD have limitations, necessitating novel therapeutic approaches.
- Drug-coated balloons (DCBs) represent an emerging technology for PAD intervention.
Purpose of the Study:
- To evaluate the safety and efficacy of drug-coated balloon (DCB) therapy in patients with peripheral arterial disease (PAD).
- To analyze immediate and follow-up clinical outcomes, including ankle-brachial index (ABI) and symptom relief.
- To assess the real-world effectiveness of DCB treatment in a diverse PAD patient cohort.
Main Methods:
- Retrospective, single-center study of 75 patients undergoing DCB therapy for PAD.
- Ankle-brachial index (ABI) measurements pre- and post-intervention.
- Telephone assessment of intermittent claudication, rest pain, and ulcer healing during follow-up.
Main Results:
- Significant improvement in postoperative ABI compared to preoperative values (0.911 vs 0.686).
- Absence of intermittent claudication and rest pain in Rutherford grades III and IV patients post-treatment.
- Low amputation rate of 4.1% observed during the follow-up period.
Conclusions:
- Drug-coated balloon (DCB) therapy demonstrates safety and effectiveness in treating peripheral arterial disease in a real-world setting.
- DCB treatment leads to favorable clinical outcomes, including symptom improvement and limb salvage.
- Further prospective studies are recommended to confirm these findings and explore long-term efficacy.
Objective:
This retrospective single-center study aimed to analyze immediate and follow-up results of using drug-coated balloons (DCBs) for treating peripheral arterial disease.
Methods:
In this study, we identified a total of 75 patients who underwent DCB therapy at our institution. The ankle-brachial index (ABI) was measured before and after intervention. Intermittent claudication and whether there was healing of ulcers were determined by telephone.
Results:
The cohort consisted of 56 men and 19 women aged 38 to 87 years (68 ± 12 years). Twenty-three patients had Rutherford grade III, 15 had Rutherford grade IV, and 37 had Rutherford grade V. Seventeen patients had stents and 18 had the Rotarex system used. The postoperative ABI was significantly greater than the preoperative ABI (0.911 ± 0.173 vs 0.686 ± 0.249). Good results for treatment were obtained. Intermittent claudication and rest pain did not occur in subjects with Rutherford grades III and IV during follow-up. The amputation rate was 4.1% among all patients using DCB therapy during follow-up.
Conclusions:
DCB therapy is safe and effective for treating peripheral arterial disease in real-world patients. Future prospective studies on this issue are recommended.
More Related Videos
06:53A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:26Peripheral Artery Disease IV: Nursing Management
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:30Peripheral Artery Disease I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care